Richardson T C
Int J Rad Appl Instrum B. 1986;13(5):583-4. doi: 10.1016/0883-2897(86)90142-x.
Therapy of carcinoma of the thyroid may include the use of the radionuclide 131I, which localizes to thyroid tissue. In considering the use of another halogen, the alpha particle emitting radionuclide astatine, 211At, there is also the requirement that it too can be taken up by the thyroid. However, in view of its short half-life (7.2 h) it is important that its transport in the blood is not a factor likely to render it less available. For example, retention of 211At by red cells may retard its uptake by the thyroid. This in vitro investigation of the partitioning of the 211At between erythrocytes and plasma indicates that it is not strongly bound by the red cells in blood.
甲状腺癌的治疗可能包括使用可定位于甲状腺组织的放射性核素131I。在考虑使用另一种卤素——发射α粒子的放射性核素砹-211（211At）时，同样要求它也能被甲状腺摄取。然而，鉴于其半衰期较短（7.2小时），重要的是其在血液中的运输不会成为使其可用性降低的因素。例如，红细胞对211At的保留可能会阻碍其被甲状腺摄取。这项关于211At在红细胞和血浆之间分配的体外研究表明，它在血液中与红细胞的结合并不紧密。
